Literature DB >> 25432949

Visceral leishmaniasis infection in a fingolimod-treated multiple sclerosis patient.

A K Artemiadis1, G Nikolaou2, D Kolokythopoulos3, N Tegos4, A Terentiou2, N Triantafyllou5, I Papanastasiou2.   

Abstract

Entities:  

Keywords:  Visceral; fingolimod; infection; leishmaniasis; multiple sclerosis; side-effect

Mesh：

Substances：

Year:  2014        PMID： 25432949     DOI： 10.1177/1352458514555788

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


× No keyword cloud information.
  3 in total

Review 1.  ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).

Authors:  G Redelman-Sidi; O Michielin; C Cervera; C Ribi; J M Aguado; M Fernández-Ruiz; O Manuel
Journal:  Clin Microbiol Infect       Date:  2018-02-07       Impact factor: 8.067

2.  Case Report: Leishmaniasis in a 33-Year-Old Man with Multiple Sclerosis.

Authors:  Alvaro Guerra-Amor; Ane Lopez-Gonzalez; Pau Bosch-Nicolau; Breogan Rodriguez-Acevedo; Ana Zabalza; Elena Sulleiro; Juan Espinosa-Pereiro; Maria Luisa Aznar; Fernando Salvador; Adrián Sánchez-Montalvá; Israel Molina
Journal:  Am J Trop Med Hyg       Date:  2022-07-05       Impact factor: 3.707

3.  Case Report: Confirmation by Metagenomic Sequencing of Visceral Leishmaniasis in an Immunosuppressed Returned Traveler.

Authors:  Eloise Williams; Nicole S Isles; Torsten Seemann; Trevor Kilpatrick; Andrew Grigg; Marcel Leroi; Benjamin P Howden; Jason C Kwong
Journal:  Am J Trop Med Hyg       Date:  2020-11       Impact factor: 2.345
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.